Table 1 Comparison of baseline characteristics between patients with and without foot or ankle RA involvement
Variables | No RA involvement in the foot or ankle, n = 46 | RA involvement in the foot or ankle, n = 74 | P value |
|---|---|---|---|
Age, median (IQR), years | 45.5 (36.8–54.0) | 50.5 (38.75–58.0) | 0.09 |
Disease duration, median (IQR), months | 47.5 (7.50–80.0) | 63.0 (12.3–103.3) | 0.09 |
BMI, median (IQR), kg/m2 | 21.7 (20.5–24.0) | 22.9 (20.2–25.0) | 0.35 |
Patient global assessment, VAS (0–10), median (IQR) | 15.0 (10.0–30.0) | 30.0 (10.0–40.0) | <0.05 |
CRP, median (IQR), mg/dl | 0.40 (0.34–0.95) | 0.40 (0.15–1.13) | 0.97 |
ESR, median (IQR), mm/h | 18.5 (10.0–40.0) | 27.0 (11.8–43.0) | 0.35 |
DAS28-ESR, median (IQR) | 3.07 (2.50–4.10) | 4.08 (3.05–5.07) | <0.05 |
Female, n (%) | 45 (97.8) | 68 (91.9) | 0.25 |
RF positive, n (%) | 39 (84.8) | 65 (87.8) | 0.63 |
ACPA positive, n (%) | 42 (91.3) | 65 (89.0) | 0.86 |
Medications, n (%) | |||
Glucocorticoid | 35 (76.1) | 54 (73.0) | 0.71 |
NSAID | 38 (82.6) | 67 (90.5) | 0.20 |
Methotrexate | 44 (95.7) | 67 (90.5) | 0.48 |
Conventional DMARDsa | 45 (97.8) | 72 (97.3) | 1.00 |
Biologic DMARDsb | 7 (15.2) | 33 (44.6) | <0.05 |
EQ-5D, median (IQR) | 0.81 (0.75–0.86) | 0.76 (0.69–0.84) | <0.05 |
HAQ-DI (0–3), median (IQR) | 0.38 (0–0.5) | 0.63 (0.13–1.16) | <0.05 |
RA involvement, n (%) | |||
Forefoot | 0 | 32 (43.2) | NA |
Midfoot | 0 | 24 (32.4) | NA |
Hindfoot | 0 | 46 (62.2) | NA |
Ankle | 0 | 4 (5.4) | NA |
Foot deformity, n (%) | |||
Hallux valgus, | 8 (17.4) | 18 (24.3) | 0.37 |
Metatarsus primus varus | 16 (34.8) | 22 (29.7) | 0.56 |
Splayfoot | 0 | 2 (2.7) | 0.52 |
Pes planus | 43 (93.5) | 71 (95.9) | 0.67 |